Tag: ATH
Dr David Stamler steps-up as chief executive officer to lead Alterity Therapeutics’ commercialisation plans
Alterity Therapeutics (ASX: ATH) has appointed Dr David Stamler to lead the company as chief executive officer and spearhead the company’s commercialisation plans for drug ATH434 in treating parkinson...
Alterity Therapeutics to commercialise technology that breaks antibiotic resistance
The University of Queensland’s commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology in combating superbugs.
UniQuest has ...
Alterity Therapeutics collars US patent for next generation compounds
Alterity Therapeutics’ (ASX: ATH) has collared the US patent for its next generation compounds that are designed to assist in treating Parkinson’s and Alzheimer’s as well as other neurodegenerative co...
New clinical data confirms efficacy of Alterity Therapeutics’ lead drug for treatment of multiple system atrophy
Neurodegenerative disease-focused biotech Alterity Therapeutics (ASX: ATH) has announced that new clinical and experimental pharmacology data for its lead candidate ATH434 has confirmed the drug can r...
FDA provides development pathway for Alterity Therapeutics’ drug to treat multiple system atrophy
Alternative drug developer Alterity Therapeutics (ASX: ATH) has received guidance from the US Food and Drug Administration (FDA) on the development pathway for its experimental treatment for multiple ...
